Article Sidebar

Published: 2026-06-29
Abstract Views: 5
DOI: https://doi.org/10.52163/yhc.v67iCD7.5614
Issue
Vol. 67 No. CĐ7- Trường ĐH Y Dược Hải Phòng
Section
Articles
How to Cite
Thương, P. V., Dương, T. T., & Sơn, V. N. (2026). EVALUATE THE EFFICACY OF LONG-COURSE NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE II–III LOW RECTAL CANCER TREATED AT 108 MILITARY CENTRAL HOSPITAL. Vietnam Journal of Community Medicine, 67(CĐ7- Trường ĐH Y Dược Hải Phòng). https://doi.org/10.52163/yhc.v67iCD7.5614

EVALUATE THE EFFICACY OF LONG-COURSE NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE II–III LOW RECTAL CANCER TREATED AT 108 MILITARY CENTRAL HOSPITAL.

Pham Van Thuong1, Trieu Trieu Duong2, Vu Ngoc Son3
1 Hai Phong University of Medicine and Pharmacy
2 Tam Anh Hospital
3 108 Military Central Hospital

Main Article Content

Abstract

Objective: To evaluate the efficacy of long-course neoadjuvant chemoradiotherapy in patients with stage II–III low rectal cancer treated at 108 Military Central Hospital.


Subjects and methods: A retrospective descriptive study was conducted on 83 patients with stage II–III low rectal cancer who received long-course neoadjuvant chemoradiotherapy at 108 Military Central Hospital from August 2018 to August 2023.


Results: Tumor size decreased from 5.17 ± 1.90 cm to 3.96 ± 1.94 cm (p < 0.001). The proportion of tumors staged as T3–4 on MRI decreased from 95.2% to 62.7%. The rate of regional lymph node positivity on MRI decreased from 94.0% to 67.5% (p < 0.001). The proportion of patients with CEA > 5 ng/mL decreased from 48.2% to 10.8%. Overall, 97.6% of patients completed the chemoradiotherapy regimen as planned. On post-treatment MRI, mrTRG 1–3 accounted for 77.1%. The rates of pathological response were 22.9% for complete response (TRG 1), 16.9% for TRG 2, 43.4% for TRG 3, 12.0% for TRG 4, and 4.8% for TRG 5.


Conclusion: Long-course preoperative chemoradiotherapy in patients with lower-third rectal cancer is a safe and effective treatment modality. It contributes to tumor downsizing, downstaging of mural invasion, reduction in MRI-detected lymph node involvement, decreased CEA levels, and a high rate of favorable histopathological response.

Article Details

Keywords

low rectal cancer; long-course neoadjuvant chemoradiotherapy  

References

1. Sauer R., Liersch T., Merkel S., et al (2012). Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 30, 1926-1933.
2. Sauer R., Becker H., Hohenberger W., et al. (2004). Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N Engl J Med. 351, 1731-1740.
3. Patel U.B., Taylor F., Blomqvist L., et al (2011). Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 29(28), 3753-60.
4. Mandard A.M., Dalibard F., Mandard J.C., et al (1994). Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 73(11), 2680-6.
5. Benson A.B., Venook A.P., Adam M., et al (2024). NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 22(6), 366-375.
6. Hofheinz R.D., Fokas E., Benhaim L., et al (2025). Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 36(9), 1007-1024.
7. Joo J.I., Lim S.W., Oh B.Y. (2021). Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy. Ann Coloproctol. 37(3), 179-185.
8. Bahadoer R.R., Dijkstra E.A., van Etten B., et al (2021). Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(1), 29-42.
9. Santos M.D., Silva C., Rocha A., et al (2013). Tumor regression grades: can they influence rectal cancer therapy decision tree? Int J Surg Oncol.
10. Song C., Chung J.H., Kang S.B. (2018). Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System. Cancers (Basel). 10(9), 319.